Postmenopausal Patients with Node-Positive Resectable Breast Cancer

摘要: Anthracyclines are among the most active drugs for treatment of advanced breast cancer. Epirubicin has been found to be as effective doxorubicin at equimolar doses but significantly better tolerated, especially in terms alopecia, leucopenia, and cardiac toxicity. The role anthracycline-containing regimens adjuvant cancer studied by only a few clinical trial teams. In 1986, French Adjuvant Study Group (FASG) began randomised aimed investigate concept dose intensity well optimal duration patients with early Between 1986 1990, 621 were included trial, whom 595 evaluable. Patients 1 3 groups: A (n = 207) received FEC 50 (fluorouracil 500 mg/m2, epirubicin mg/m2 plus cyclophosphamide mg/m2) every 21 days 6 cycles; B 193) C 195) 75 cycles. Locoregional radiotherapy was administered after third cycle chemotherapy all arms. Clinical prognostic factors similar between groups.